An Expert Monograph on Thymosin Beta-4 (Timbetasin): Mechanisms, Clinical Development, and Therapeutic Potential

Executive Summary

Thymosin beta-4 (Tβ4), also known by the recommended International Nonproprietary Name (INN) timbetasin, is an investigational, naturally occurring 43-amino acid peptide with a remarkable array of biological activities centered on tissue protection, repair, and regeneration. This monograph provides a comprehensive analysis of Tβ4, synthesizing its physicochemical properties, dual mechanisms of action, extensive preclinical evidence, and complex clinical development history. The therapeutic rationale for Tβ4 is founded on its pleiotropic functions, which include potent pro-migratory, pro-angiogenic, anti-inflammatory, anti-apoptotic, and anti-fibrotic effects. These activities stem from a unique dual-mechanism profile: intracellularly, it is the primary G-actin sequestering protein, regulating cytoskeletal dynamics, while extracellularly, it functions as a "moonlighting" signaling molecule released at sites of injury to orchestrate the entire healing cascade.

The clinical development of Tβ4 has been pursued across a diverse range of indications. The most advanced program is the ophthalmic formulation RGN-259, which has completed multiple Phase 3 trials for Dry Eye Syndrome (DES) and is in late-stage development for Neurotrophic Keratopathy (NK), an orphan indication for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). While the DES program has yielded mixed results on primary endpoints, the NK program has shown strong, clinically meaningful efficacy signals. Early-stage clinical trials in dermal wound healing for conditions such as venous stasis ulcers and pressure ulcers have shown trends toward accelerated repair but have not progressed to later stages. Emerging clinical evidence in cardiovascular disease, particularly in patients with ST-segment elevation myocardial infarction (STEMI), suggests a significant potential to improve cardiac function post-injury.

A consistent and defining feature of Tβ4 across all human trials is its excellent safety and tolerability profile, with no dose-limiting toxicities or serious adverse events reported even at high intravenous doses. This favorable safety profile represents a key strategic asset for its continued development. A pivotal event in its regulatory journey was the 2020 reclassification by the FDA from a new drug entity to a biologic, mandating a Biologics License Application (BLA) for approval. This change significantly enhances its commercial potential by extending market exclusivity from 5 to 12 years upon approval. It is critical to distinguish the rigorously studied, full-length Tβ4 peptide from unregulated synthetic fragments, such as TB-500, which are marketed without regulatory oversight. Overall, Thymosin beta-4 represents a promising therapeutic candidate with a validated mechanism, a strong safety record, and a clear, albeit challenging, path toward potential approval, particularly in orphan ophthalmic and potentially in acute cardiovascular indications.

1.0 Introduction to Thymosin Beta-4 (Tβ4): A Multifunctional Regenerative Peptide

1.1 Discovery, Classification, and Biological Context

Thymosin beta-4 (Tβ4) is a highly conserved, naturally occurring peptide that was first isolated from calf thymus tissue.[1] Initially, it was categorized as a thymic hormone, belonging to the broader thymosin family of peptides, which are classified into three groups—alpha (

α), beta (β), and gamma (γ)—based on their isoelectric point.[3] Tβ4 is a member of the β-thymosin group, which is characterized by an isoelectric point between 5.0 and 7.0.[3]

Subsequent research revealed that Tβ4 is the most abundant and biologically active member of the β-thymosin family in humans and other mammals, constituting approximately 70-80% of the total β-thymosin content.[1] Far from being confined to the thymus, Tβ4 is a ubiquitous molecule found in nearly all tissues and circulating cells, with the notable exception of red blood cells.[1] Particularly high concentrations are present in cells and fluids integral to injury response and immunity, such as platelets, macrophages, wound fluid, the spleen, and the thymus.[3]

1.2 Overview of Pleiotropic Functions and Therapeutic Rationale

The therapeutic rationale for Tβ4 is built upon its pleiotropic, or multifunctional, nature as a central mediator of tissue protection, repair, and regeneration.[11] Following an injury, Tβ4 is released from cells such as platelets and macrophages, where it acts to shield tissues from further damage, mitigate apoptosis (programmed cell death) and inflammation, and stimulate the migration of reparative cells to the wound site.[7]

This broad spectrum of activity provides the scientific foundation for investigating Tβ4 across a diverse range of clinical indications. Its key biological activities include:

• Promotion of angiogenesis (the formation of new blood vessels).[1]
• Acceleration of wound healing in various tissues.[8]
• Modulation of inflammation, typically by down-regulating pro-inflammatory pathways.[2]
• Reduction of apoptosis and fibrosis (scar tissue formation).[1]
• Promotion of stem/progenitor cell migration and differentiation.[13]

This multifaceted profile has justified its clinical evaluation in dermal, corneal, cardiac, and central nervous system (CNS) injuries, positioning Tβ4 as a uniquely versatile therapeutic candidate.[1]

The entire therapeutic premise of Tβ4 is rooted in a functional duality. Initially, its role was understood primarily in an intracellular context as the principal protein responsible for sequestering globular actin (G-actin), a fundamental homeostatic process essential for maintaining cellular structure and enabling motility.[2] However, the discovery of high concentrations of Tβ4 in wound fluid and its release from platelets at injury sites strongly suggested an additional, extracellular function.[7] Subsequent research confirmed that the

exogenous administration of Tβ4 triggers potent biological responses—such as cell migration, angiogenesis, and anti-inflammation—that could not be explained solely by its intracellular activity, especially in target cells that already contain high endogenous levels of the peptide.[8] This led to the characterization of Tβ4 as a "moonlighting" protein, one that performs distinct functions depending on its location.[6] This dual functionality is the cornerstone of its therapeutic potential; its efficacy as an administered drug relies on its capacity to act as an extracellular signaling molecule that initiates a comprehensive cascade of regenerative events. This understanding reframes Tβ4 from a mere structural component into a master regulator of tissue repair, providing a robust rationale for its investigation in a wide array of diseases.

2.0 Physicochemical Properties and Molecular Structure

2.1 Identification and Nomenclature

Thymosin beta-4 is identified by a consistent set of names and chemical identifiers across scientific and regulatory databases.

• Generic Name: Thymosin beta-4.[16]
• Recommended INN: Timbetasin.[6]
• Synonyms: Common synonyms include Tβ4, TB4X, PTMB4, Fx peptide, RH-OLIGOPEPTIDE-4, and HUMAN OLIGOPEPTIDE-16.[9]
• Key Identifiers:
• DrugBank ID: DB12003.[16]
• CAS Number: 77642-24-1.[16]
• UNII (Unique Ingredient Identifier): 549LM7U24W.[16]
• UniProt (Protein Knowledgebase): P62328.[18]

2.2 Amino Acid Sequence and Primary Structure

Tβ4 is a polypeptide composed of 43 amino acids.[1] The N-terminus of the mature peptide is acetylated, a modification crucial for its biological activity and stability.[7]

• Human Amino Acid Sequence: The sequence for human Tβ4 is: SDKPDMAEI EKFDKSKLKK TETQEKNPLP SKETIEQEKQ AGES.6

2.3 Molecular Formula, Weight, and Predicted Structure

The molecular characteristics of Tβ4 have been well-defined through multiple analytical methods.

• Molecular Formula: C212​H350​N56​O78​S.[1]
• Molecular Weight: Reported values are highly consistent, typically cited as approximately 4963 g/mol or 4.9 kDa.[9] Wikipedia reports a value of 4921 g/mol.[6] These minor discrepancies are common for large peptides and depend on the specific calculation method used.
• Secondary and Tertiary Structure: Tβ4 is classified as an Intrinsically Disordered Protein (IDP), meaning it lacks a stable, folded three-dimensional structure in aqueous solution.[6] This high degree of flexibility is a defining feature, to the extent that 3D conformer generation is computationally disallowed due to the large number of atoms and undefined stereocenters.[22] However, upon binding to its partners, such as actin, Tβ4 adopts a more defined conformation. Predictive models and experimental data suggest the formation of two alpha-helices, located at amino acid residues 4-12 and 32-40, which are critical for its interaction with actin.[14]

The structural plasticity of Tβ4 is not a limitation but rather the molecular basis for its multifunctionality. This identity as an IDP directly explains its capacity for "protein moonlighting." Because it is not locked into a single rigid structure, it can adapt its conformation to bind with multiple, structurally diverse partners, thereby mediating a wide range of biological effects.[6] The formation of its alpha-helical domains specifically upon interaction with actin is a classic example of this induced-fit mechanism.[23] This provides a unifying physicochemical principle that connects its molecular structure to its pleiotropic physiological roles.

2.4 Physical and Chemical Characteristics

• Type: Tβ4 is classified as a biotech product and a protein-based therapy.[16]
• Solubility: It is a water-soluble peptide, consistent with its presence in cytosolic and extracellular fluids.[8]
• Isoelectric Point (pI): The pI of Tβ4 is reported to be 5.1, classifying it as an acidic peptide.[25]

Parameter	Value	Source(s)
Generic Name	Thymosin beta-4	16
INN	Timbetasin	17
DrugBank ID	DB12003	16
CAS Number	77642-24-1	16
UNII	549LM7U24W	16
Molecular Formula	C212​H350​N56​O78​S	20
Molecular Weight	~4963 g/mol (~4.9 kDa)	9
Amino Acid Count	43	1
Human Sequence	SDKPDMAEI EKFDKSKLKK TETQEKNPLP SKETIEQEKQ AGES	6
Type	Biotech / Protein-Based Therapy	16
Solubility	Water-soluble	8
Isoelectric Point (pI)	5.1	25

3.0 Pharmacodynamics: The Dual Mechanisms of Action

The diverse biological effects of Thymosin beta-4 are attributable to two distinct but complementary mechanisms of action: a well-characterized intracellular role in regulating the cytoskeleton and a multifaceted extracellular role as a signaling molecule that orchestrates tissue repair.

3.1 Intracellular Role: G-Actin Sequestration and Cytoskeletal Dynamics

The primary and most fundamental intracellular function of Tβ4 is to act as the principal G-actin (globular, monomeric actin) sequestering protein in the cytoplasm of most eukaryotic cells.[1] It forms a stable 1:1 complex with G-actin, thereby preventing its polymerization into F-actin (filamentous actin).[6] This activity is crucial for maintaining a large pool of unpolymerized actin monomers, which can be rapidly mobilized for filament assembly. Tβ4 thus functions as a critical buffer, maintaining the dynamic equilibrium between monomeric and polymeric actin that is essential for cellular processes requiring rapid cytoskeletal reorganization, such as cell migration, division, and maintenance of cell shape.[6]

The structural basis for this interaction has been elucidated through X-ray crystallography. Tβ4 binds to actin via two distinct alpha-helical regions: an N-terminal helix (residues 5-11) and a C-terminal helix (residues 31-39). These helices span the nucleotide-binding cleft of the actin monomer, effectively capping both the "barbed" and "pointed" ends and sterically hindering its incorporation into a growing filament.[26] A highly conserved sequence within Tβ4, LKKTET (residues 17-23), is recognized as a central component of this actin-binding motif.[6]

The regulation of actin dynamics is a coordinated process involving multiple proteins. Tβ4 and profilin are the two major G-actin sequestering proteins in the cell. They can coexist with actin to form a ternary complex (Tβ4:actin:profilin) and engage in a competitive equilibrium that precisely controls the availability of actin monomers for filament elongation at specific sites within the cell.[23]

3.2 Extracellular "Moonlighting" and Receptor-Mediated Signaling

Upon tissue injury, Tβ4 is released from damaged cells and activated platelets, allowing it to function as an extracellular signaling molecule.[6] This extracellular activity, termed "protein moonlighting," is responsible for the majority of its observed therapeutic effects. It is considered highly unlikely that these effects are mediated by intracellular actin sequestration, as this would require uptake by target cells that already possess high endogenous concentrations of Tβ4.[6]

This implies the existence of specific cell-surface receptors that bind extracellular Tβ4 and initiate downstream signaling cascades. While the full range of these receptors has not been definitively identified, one proposed candidate is the β subunit of cell surface-located ATP synthase, which could trigger purinergic signaling pathways upon Tβ4 binding.[6] It is this receptor-mediated signaling that drives the pro-regenerative cellular behaviors observed with exogenous Tβ4 administration, including the promotion of endothelial cell and keratinocyte migration, the stimulation of angiogenesis, and the modulation of inflammatory responses.[15]

3.3 Analysis of Key Signaling Pathways

Tβ4 exerts its pleiotropic effects by modulating a network of critical intracellular signaling pathways that govern cell survival, proliferation, inflammation, and tissue remodeling.[13]

3.3.1 Pro-regenerative Pathways

• Angiogenesis Pathways (VEGF and Notch): Tβ4 is a potent angiogenic factor. It stimulates the formation of new blood vessels by enhancing endothelial cell viability, migration, and tube formation.[3] This is achieved, in part, by upregulating the expression of key angiogenic molecules, most notably Vascular Endothelial Growth Factor (VEGF) and angiopoietin-1.[3] Furthermore, Tβ4-induced angiogenesis is also mediated through the Notch signaling pathway, specifically involving Notch1 and Notch4, which can work in concert with VEGF to drive vascular development.[13]
• PI3K/Akt Survival Pathway: A central mechanism for Tβ4's anti-apoptotic and pro-survival effects is its ability to activate the Phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. This pathway is crucial for protecting cardiomyocytes and endothelial cells from cell death following ischemic injury and for promoting cell migration and proliferation.[13]
• Wnt/β-catenin Pathway: Tβ4 has been shown to activate the Wnt/β-catenin pathway, a signaling cascade fundamentally involved in development and stem cell regulation. This mechanism is implicated in its ability to promote hair follicle formation and may contribute to its regenerative effects in other tissues, such as in limb regeneration models.[13]

3.3.2 Anti-inflammatory and Anti-fibrotic Pathways

• NF-κB Pathway: Tβ4 exerts powerful anti-inflammatory effects primarily by downregulating the Nuclear Factor kappa B (NF-κB) signaling pathway. NF-κB is a master transcription factor that drives the expression of numerous pro-inflammatory cytokines. Tβ4 inhibits NF-κB activation by preventing the phosphorylation and degradation of its inhibitory subunit, IκB. This blockade effectively suppresses the production of key inflammatory mediators such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1β (IL-1β), and Interleukin-6 (IL-6).[13]
• TGF-β Pathway: Tβ4 plays a crucial role in preventing fibrosis, or excessive scarring. It achieves this by inhibiting the Transforming Growth Factor-beta (TGF-β)/Smad pathway, which is a primary driver of fibrotic processes in organs like the liver and kidney and in dermal wounds.[13] Interestingly, Tβ4 can also act synergistically with TGF-β in a different context to regulate the proper development of mural cells, which are essential for blood vessel stability.[37]

The coordinated modulation of these pathways reveals Tβ4's role as both a "first responder" and a "master coordinator" of tissue repair. Its immediate release from platelets at a wound site allows it to first suppress potentially damaging inflammation via NF-κB inhibition.[7] Concurrently, it initiates the proliferative phase by promoting the migration of key reparative cells like keratinocytes and endothelial cells.[15] It then stimulates angiogenesis through the VEGF and Notch pathways to vascularize the new tissue.[3] Finally, during the remodeling phase, it minimizes scar formation by inhibiting the pro-fibrotic TGF-β pathway and reducing the number of myofibroblasts.[7] This ability to orchestrate the entire healing cascade in a temporally appropriate manner explains its efficacy in complex regenerative processes and distinguishes it from single-action growth factors.

4.0 Pharmacokinetic Profile

The pharmacokinetic (PK) properties of Thymosin beta-4, particularly its distribution and elimination, are critical factors influencing its clinical development and therapeutic application. While comprehensive ADME (Absorption, Distribution, Metabolism, Excretion) data remains incomplete in public databases [16], clinical and preclinical studies provide key insights into its behavior

in vivo.

4.1 Distribution and Bioavailability

As an endogenous peptide, Tβ4 is naturally distributed throughout the body, found in almost all tissues and cell types, with the exception of red blood cells.[1] Its high concentration in platelets and wound fluid confirms its physiological role in localizing to sites of injury.[9] Studies have also documented differential expression patterns between fetal and adult tissues, such as in the gastrointestinal tract, suggesting its involvement in developmental processes.[38]

Specific bioavailability data for various administration routes are not detailed in the available materials. However, the short half-life and the exploration of advanced delivery systems, such as fibrin-targeting nanoparticles for cardiac repair, suggest that systemic bioavailability and targeted tissue exposure are significant challenges for therapeutic applications.[7]

4.2 Metabolism and Key Metabolites

Detailed in vivo metabolic pathways for Tβ4 have not been fully elucidated.[7] However,

in vitro enzymatic studies have identified potential metabolic breakdown products. For instance, the enzyme Leucine aminopeptidase (LAP) has been shown to cleave Tβ4, producing the N-terminal fragment Ac-Tβ[1-14].[7]

The most significant and functionally relevant metabolite of Tβ4 is the N-terminal tetrapeptide, N-acetyl-ser-asp-lys-pro (Ac-SDKP). This smaller peptide is enzymatically cleaved from the full-length Tβ4 and possesses its own distinct biological activities, including anti-fibrotic and pro-angiogenic properties. The actions of Ac-SDKP are thought to contribute to the overall therapeutic effect of the parent Tβ4 molecule, particularly in the context of fibrosis and angiogenesis.[6]

4.3 Elimination and Dose-Dependent Half-Life

The primary route of elimination for Tβ4 has not been specified.[16] However, a Phase 1 clinical trial in healthy human volunteers provided crucial data on its plasma half-life following intravenous administration. The study revealed a clear dose-dependent relationship, where the half-life increased with higher doses [41]:

• At a 42 mg single dose, the mean half-life was 0.95 hours.
• At a 140 mg single dose, the mean half-life was 1.2 hours.
• At a 420 mg single dose, the mean half-life was 1.9 hours.
• At a 1260 mg single dose, the mean half-life was 2.1 hours.

4.4 Identified Gaps in ADME Data

There are significant gaps in the publicly available ADME profile of Tβ4. Key missing information includes absorption kinetics for the subcutaneous and topical routes used in clinical trials, a comprehensive map of the metabolic enzymes involved beyond initial cleavage, and the definitive primary route of excretion (e.g., renal, hepatic).

The short plasma half-life of Tβ4 is a critical pharmacokinetic characteristic that profoundly shapes its clinical development strategy. A half-life of just over two hours, even at a very high intravenous dose of 1260 mg, indicates rapid clearance from systemic circulation.[41] For systemic indications like cardiac or neurological repair, this presents a major challenge, as maintaining a therapeutic concentration at the target tissue requires either frequent, repeated dosing or very high initial doses, as seen in trial designs employing daily or alternate-day injections.[43] This PK limitation is the direct impetus for research into advanced delivery technologies, such as the fibrin-targeting nanoparticles designed to concentrate and retain Tβ4 at the site of myocardial injury.[39] Conversely, for local applications like the ophthalmic drops (RGN-259) or dermal gels, the short systemic half-life is less of a concern and may even be advantageous, as it minimizes systemic exposure and the potential for off-target effects. This pharmacokinetic profile helps explain why the locally administered ophthalmic program is the most advanced in the Tβ4 clinical pipeline.

5.0 Preclinical Evidence and Therapeutic Rationale

An extensive body of preclinical research in both in vitro and in vivo models has established the therapeutic rationale for Tβ4 across a wide range of injuries and diseases. These studies have consistently demonstrated its potent regenerative capabilities and have provided the scientific foundation for its progression into human clinical trials.

5.1 In Vitro and In Vivo Models of Tissue Repair

• Dermal Healing: Tβ4 has shown remarkable efficacy in promoting the healing of skin wounds in numerous animal models. It accelerates repair in normal, aged, and diabetic mice, as well as in models where healing is impaired by steroid treatment.[10] Mechanistically, it enhances the key processes of wound healing, including re-epithelialization (keratinocyte migration), collagen deposition, and angiogenesis.[10] An interesting associated finding is its ability to promote hair growth in and around the treated wound area.[10]
• Corneal Healing: In the context of ophthalmology, topical application of Tβ4 has been shown to significantly accelerate corneal healing and reduce inflammation in various injury models, such as those induced by alkali burns, chemical debridement (heptanol), and experimental dry eye.[2] A crucial observation in these studies is that Tβ4 promotes the migration of epithelial cells to cover the defect without inducing neovascularization, thereby preserving the critical avascular nature of the cornea.[10]

5.2 Cardioprotective and Angiogenic Effects in Animal Models

Preclinical studies in cardiovascular disease models have demonstrated profound protective and regenerative effects. In both murine (mouse) and porcine (pig) models of myocardial infarction (heart attack), the administration of exogenous Tβ4 after the ischemic event has been shown to improve overall cardiovascular function, reduce the size of the infarct and subsequent scar formation, inhibit myocardial cell death, and promote the survival of cardiomyocytes.[1] Tβ4 stimulates cardiac repair by promoting angiogenesis and the formation of collateral blood vessels. It achieves this by activating quiescent epicardial progenitor cells (cells on the outer surface of the heart) and inducing their differentiation into new vascular cells.[3] Furthermore, Tβ4 has been identified as an essential factor for the proper development of mural cells (smooth muscle cells that support blood vessels), where it acts synergistically with TGF-β to ensure vessel wall stability.[37]

5.3 Neuroprotective and Neurorestorative Findings

The potential of Tβ4 extends to the central nervous system. In rat models of Traumatic Brain Injury (TBI), treatment with Tβ4, even when initiated with a delay after the initial injury, has been shown to reduce the volume of the cortical lesion, decrease cell loss in the hippocampus, enhance neurogenesis (the formation of new neurons), and lead to significant improvements in functional recovery, as measured by both sensorimotor and spatial learning tasks.[50] Beyond TBI, Tβ4 has demonstrated neuroprotective effects in models of excitotoxicity (neuronal damage caused by overstimulation from neurotransmitters like glutamate).[53] Its potential is also being explored in neurodegenerative conditions such as Alzheimer's disease and prion disease, where it has been shown to reduce apoptosis and oxidative stress in neuronal cells.[36]

5.4 Anti-inflammatory and Cytoprotective Studies

Tβ4 possesses significant anti-inflammatory and cell-protective properties. In mouse models of endotoxin-induced septic shock, administration of Tβ4 reduced lethality by down-regulating the systemic surge of inflammatory cytokines.[55] In

in vitro studies, it has been shown to inhibit apoptosis in corneal epithelial cells exposed to common toxins like ethanol and the preservative benzalkonium chloride.[14] An oxidized form of the peptide, Tβ4-sulfoxide, has also been identified as a potent mediator that attenuates inflammatory cell infiltration and promotes wound healing in the heart.[56]

The development of Tβ4 demonstrates a robust and logical translation from preclinical research to clinical investigation. The broad spectrum of activities observed in animal models—including dermal healing in challenging contexts like diabetes, rapid corneal repair, and significant cardioprotection—directly corresponds to the indications selected for human trials. Moreover, the outcomes observed in early-phase human studies, such as an accelerated rate of repair in wounds and anti-inflammatory effects in the eye, align closely with the preclinical predictions.[6] This consistency between the preclinical data and the signals of efficacy in human trials, even when those signals do not achieve statistical significance on primary endpoints, serves to validate the underlying mechanisms of action in humans and provides strong support for continued clinical development.

6.0 Clinical Development and Efficacy Analysis

The clinical development of Thymosin beta-4 has been ambitious, spanning multiple therapeutic areas including ophthalmology, dermal wound healing, and cardiovascular disease. The program is characterized by a leading late-stage asset in ophthalmology and promising, albeit early, results in other indications.

6.1 Ophthalmic Indications: The RGN-259 Program

The most advanced clinical application of Tβ4 is RGN-259, a sterile, preservative-free ophthalmic eye drop formulation.[59] This program has focused on two primary indications.

6.1.1 Dry Eye Syndrome (DES)

• Clinical Program: The development for DES has been extensive, involving a series of three large, multicenter Phase 3 trials in the U.S. known as ARISE-1, ARISE-2, and ARISE-3, which collectively enrolled over 1,600 patients.[59] A fourth Phase 3 trial, ARISE-4, is currently being planned.[62]
• Efficacy: The ARISE trials did not consistently meet their pre-specified co-primary endpoints with statistical significance.[59] This is a common challenge in DES trials due to high placebo response rates and patient heterogeneity. However, subsequent pooled data and post-hoc analyses of patient subgroups revealed statistically significant improvements with RGN-259 in both a key sign of the disease (corneal staining) and key symptoms (ocular discomfort, grittiness).[59] A notable feature was the rapid onset of action, with symptom improvements observed as early as one to two weeks into treatment.[60]
• Safety: Across all trials, RGN-259 demonstrated an excellent and consistent safety profile.[59]
• Phase 2 Foundation: The rationale for the large Phase 3 program was supported by a successful Phase 2 trial (NCT01393132) in patients with severe dry eye. This study showed statistically significant improvements in both ocular discomfort (p=0.0141) and total corneal fluorescein staining (p=0.0108) that notably persisted for 28 days after treatment had stopped.[58]

6.1.2 Neurotrophic Keratopathy (NK)

• Regulatory Status: Tβ4 has received Orphan Drug Designation from the U.S. FDA for the treatment of NK, a rare and serious degenerative corneal disease.[18]
• Clinical Program: An initial Phase 3 trial, SEER-1 (NCT02606355), was completed in a small cohort of 18 patients.[59] A subsequent, larger Phase 3 trial, SEER-2 (NCT05555589), is currently recruiting patients.[67]
• Efficacy: In the SEER-1 trial, RGN-259 demonstrated a strong, clinically meaningful efficacy signal. After four weeks of treatment, 6 out of 10 patients (60%) in the RGN-259 group achieved complete healing of their corneal defect, compared to only 1 out of 8 patients (12.5%) in the placebo group.[59] Due to the very small sample size required for an orphan indication, this difference showed a strong trend but did not reach the conventional threshold for statistical significance on the primary endpoint ( p=0.0656).[69] However, a pre-specified secondary endpoint evaluating the durability of healing at day 43 (two weeks after treatment cessation) was statistically significant ( p=0.0359), confirming a lasting treatment effect.[59]
• Safety: The treatment was confirmed to be safe and well-tolerated in this fragile patient population.[59]

6.2 Dermal Wound Healing: Review of Phase 2 Trials

Tβ4 has been evaluated in Phase 2 clinical trials for several types of chronic dermal wounds. While these studies established its safety and showed positive trends, they did not achieve their primary efficacy endpoints, and development in these indications has not progressed to Phase 3.[6]

• Venous Stasis Ulcers (NCT00832091): A completed Phase 2 trial in patients with venous ulcers found a trend towards a faster rate of healing in the group treated with a 0.03% Tβ4 gel, particularly by week 8. However, at the study's conclusion on day 84, there was no statistically significant difference compared to the placebo group.[6]
• Pressure Ulcers (NCT00382174): Similarly, a Phase 2 trial in patients with pressure ulcers showed a trend toward accelerated healing with a 0.02% Tβ4 gel by week 4, but this advantage was not maintained through the final 84-day endpoint.[6]
• Epidermolysis Bullosa (EB) (NCT00311766): Tβ4 also has an orphan drug designation for EB, a severe genetic blistering disorder.[18] A Phase 2 trial for this indication was ultimately terminated.[72] The results had shown a trend toward faster healing with a 0.03% gel, but this did not reach statistical significance at the 56-day endpoint.[6]

6.3 Cardiovascular Repair: Emerging Evidence

Clinical evidence for Tβ4 in cardiovascular disease, while still in early stages, is highly promising and aligns with the robust preclinical data.

• ST-Segment Elevation Myocardial Infarction (STEMI): A pilot clinical trial conducted in China enrolled 10 STEMI patients who received transplants of endothelial progenitor cells (EPCs). In the experimental group (n=5), the EPCs were pre-treated with Tβ4 before transplantation. At the 6-month follow-up, this group demonstrated remarkable and statistically significant improvements in cardiac function, including a greater than 50% improvement in left ventricular ejection fraction (p<0.05) and an approximately 50% improvement in stroke volume (p<0.05) compared to the control group that received untreated EPCs.[2]
• Ischemic Heart Failure: A UK-based trial (REGENERATIVE-IHD) studying the effects of intracardiac stem cell injections made a key discovery related to Tβ4. The researchers found that patients who experienced clinical improvement following the stem cell therapy had a significant increase in their circulating plasma levels of Tβ4 just 24 hours after the injection. This finding suggests that Tβ4 may be a critical mediator of the cardiac repair induced by stem cell therapy.[49]

6.4 Neurological Applications: Preclinical Foundation for Future Trials

While human trials in neurology are not as advanced, the compelling preclinical data in models of TBI [50] and other neurological disorders [35] provide a strong scientific rationale for future clinical investigation. The developer, RegeneRx, lists Tβ4 as a clinical candidate for cardiac/neuro indications, signaling intent to pursue this area.[64]

The clinical development history of Tβ4 illustrates two distinct strategic paths. The program in Dry Eye Syndrome, a broad and heterogeneous indication, has faced significant challenges in demonstrating statistically significant efficacy over placebo in large, expensive trials, a common issue in this therapeutic area.[59] In contrast, the path in Neurotrophic Keratopathy, a rare and well-defined orphan disease, has been more direct. The condition's clear pathophysiology and the use of an objective, binary endpoint (complete wound closure) allowed a small Phase 3 trial to generate a strong and clinically meaningful efficacy signal.[59] Although this result did not meet the p-value threshold for significance due to low statistical power, it was compelling enough to justify continued late-stage development. This highlights a key strategy in modern drug development: securing an initial approval in a smaller orphan indication can de-risk an asset, validate its mechanism in humans, and build a stronger foundation with regulators for pursuing subsequent approval in larger, more commercially lucrative indications.

6.5 Summary of Clinical Trial Outcomes

Indication	Formulation / Drug Name	Trial Identifier	Phase	Status	Key Efficacy Outcome Summary
Neurotrophic Keratopathy	RGN-259	NCT05555589 (SEER-2)	3	Recruiting	To assess safety and efficacy of 0.1% RGN-259 ophthalmic solution.
Dry Eye Syndrome (DES)	RGN-259	NCT03937882 (ARISE-3)	3	Completed	Did not meet co-primary endpoints; post-hoc analysis showed significant improvement in some signs/symptoms.
Venous Stasis Ulcers	Thymosin beta-4 Gel	NCT00832091	2	Completed	Trend towards faster healing with 0.03% gel, but not statistically significant at final endpoint.
Epidermolysis Bullosa (EB)	Thymosin beta-4 Gel	NCT00311766	2	Terminated	Trend towards faster healing, but not statistically significant.
STEMI	Tβ4-treated EPCs	N/A (Pilot Trial)	Pilot	Completed	Significant improvement in LVEF (>50%, p<0.05) and stroke volume (~50%, p<0.05) at 6 months.
Severe Dry Eye	RGN-259	NCT01393132	2	Completed	Statistically significant improvement in ocular discomfort and corneal staining vs. vehicle control.

7.0 Safety, Tolerability, and Toxicology Profile

A hallmark of the Thymosin beta-4 development program is its consistently favorable safety and tolerability profile, which has been established through extensive preclinical toxicology studies and confirmed across numerous human clinical trials.

7.1 Preclinical Toxicology and Safety Pharmacology

Comprehensive non-clinical safety studies have been conducted to support the clinical development of Tβ4. According to one report, 23 distinct non-clinical studies have demonstrated its safety for intended human uses.[2] Pharmacological and toxicological assessments in multiple animal species, including rats, dogs, and monkeys, have consistently found Tβ4 to be safe and well-tolerated.[77]

Material Safety Data Sheets (MSDS) for the substance further corroborate its benign safety profile. They indicate that Tβ4 is not classified as a hazardous chemical, shows no primary irritant effect on the skin or eyes, and does not pose a flammability or explosion risk.[78] While specific LD50 (median lethal dose) values are not provided, this is typical for biologic molecules that exhibit very low acute toxicity.[78]

7.2 Clinical Safety Data from Human Trials

The safety of Tβ4 has been extensively evaluated in human subjects across multiple clinical trials, routes of administration (topical, intravenous), and patient populations. The consistent conclusion from these studies is that Tβ4 is safe and well-tolerated.[2]

A pivotal Phase 1 study evaluated intravenously administered Tβ4 in healthy volunteers. The study tested both single and multiple daily doses for 14 consecutive days, with doses escalating up to a very high level of 1260 mg. Even at the highest dose, there were no dose-limiting toxicities or serious adverse events reported.[41] In the extensive ophthalmic program for RGN-259, involving over 1,700 subjects, the safety profile has been consistently excellent, with no significant safety issues or adverse effects observed.[57]

7.3 Identified Adverse Events and Tolerability

The adverse events associated with Tβ4 administration are generally mild, infrequent, and consistent with those expected for injectable peptide therapeutics. The most commonly reported side effects include [82]:

• Mild and transient injection site reactions (e.g., redness, pain).
• Mild gastrointestinal symptoms.
• Headaches and dizziness.

In both the Phase 1 intravenous study and the Phase 2 trial for dry eye, reported adverse events were characterized as mild to moderate in intensity.[41]

7.4 Contraindications and Special Considerations

• WADA Prohibited Status: The potent biological activity of Tβ4 in promoting soft tissue recovery has led to its classification as a performance-enhancing substance. It is included on the Prohibited List by the World Anti-Doping Agency (WADA) and is banned in competitive sports.[6]
• Theoretical Tumorigenesis Concern: A theoretical long-term safety consideration for any molecule that promotes cell migration and angiogenesis is the potential to facilitate tumor growth or metastasis. Some research has associated elevated Tβ4 expression with the metastatic potential of certain tumor types.[4] While no such effects have been observed in clinical trials to date, this remains a critical area for long-term safety monitoring.

The exceptional safety profile of Tβ4 is not merely a feature but a core strategic asset that underpins its entire clinical development program. In the challenging field of drug development, the risk-benefit assessment is paramount. A molecule with a pristine safety record has a significantly lower hurdle to clear for demonstrating efficacy. For the DES program, where primary endpoints were not consistently met, the excellent safety data was a crucial factor that allowed the FDA to consider a path forward based on pooled analyses and additional trials.[59] For vulnerable populations in orphan indications like NK and EB, safety is a primary concern, and Tβ4's high degree of tolerability is a major advantage.[44] The absence of dose-limiting toxicities even at extremely high intravenous doses provides a wide therapeutic window, offering significant flexibility for developing treatments for acute systemic conditions like myocardial infarction or stroke.[41]

8.0 Regulatory Landscape and Future Directions

The regulatory and commercial landscape for Thymosin beta-4 is evolving, shaped by its investigational status, key orphan drug designations, and a pivotal reclassification that significantly enhances its long-term commercial potential.

8.1 Current Regulatory Status (FDA, EMA) and Orphan Drug Designations

• U.S. Food and Drug Administration (FDA): Thymosin beta-4 is an investigational product and is not approved by the FDA for any human use.[66] Its distribution and use are restricted to clinical trials and research settings.
• FDA Orphan Drug Designations: The FDA has granted Tβ4 orphan drug status for two rare diseases, which provides incentives for development, including tax credits, user fee waivers, and potential market exclusivity. The designated indications are:
• Treatment of Neurotrophic Keratopathy (NK).[18]
• Treatment of Epidermolysis Bullosa (EB).[18]
• European Medicines Agency (EMA): There is no information to suggest that a Marketing Authorisation Application (MAA) for Tβ4 has been submitted to or is currently under evaluation by the EMA.[85]

8.2 The Transition to a Biologic and Market Exclusivity Implications

A landmark event in the regulatory history of Tβ4 occurred on March 23, 2020. Due to the implementation of the Biologics Price Competition and Innovation Act (BPCI Act), the FDA reclassified polypeptides larger than 40 amino acids as biologics.[60] As Tβ4 is a 43-amino acid peptide, it was transitioned from being regulated as a new drug entity to being regulated as a biological product.[90]

This seemingly administrative change has profound commercial implications:

• Regulatory Pathway: Tβ4 now requires a Biologics License Application (BLA) for marketing approval, rather than a New Drug Application (NDA).[90]
• Market Exclusivity: The most significant consequence of this reclassification is the period of market exclusivity granted upon approval. Products approved under a BLA receive 12 years of market exclusivity in the United States. This is a substantial increase from the 5 years of exclusivity granted for new chemical entities approved under an NDA.[60] This extended period of protection from biosimilar competition dramatically enhances the commercial value and potential return on investment for the entire Tβ4 development program. This regulatory shift represents a pivotal commercial inflection point, making continued investment in costly late-stage trials more financially viable and increasing the asset's attractiveness to potential partners or acquirers.

8.3 The Distinction from Unregulated Analogs (e.g., TB-500)

It is critically important to differentiate the full-length, 43-amino acid Thymosin beta-4 peptide undergoing rigorous, FDA-regulated clinical trials from unregulated synthetic analogs, most notably TB-500.[29]

• Composition: TB-500 is not Tβ4. It is a synthetic fragment of Tβ4, typically comprising the seven-amino acid sequence from the actin-binding domain (LKKTETQ), often with an N-terminal acetylation.[84]
• Regulatory Status: TB-500 is not approved by the FDA or EMA for human use. It is frequently sold online as a "research chemical" or for veterinary use, and its production is entirely unregulated. This raises serious concerns regarding its purity, accurate dosing, and the potential for contaminants.[83] The use of such products constitutes self-experimentation with an unapproved and unregulated substance.[81]

8.4 Future Therapeutic Potential and Unanswered Research Questions

The multifunctional regenerative properties of Tβ4 suggest a broad potential for future clinical applications beyond the current pipeline. Based on its mechanisms of action, potential new indications could include kidney and liver disease (particularly those involving fibrosis), spinal cord injury, bone and ligament damage, and conditions associated with aging or viral infections.[12]

Despite decades of research, key questions remain. The definitive identification of the full range of extracellular receptors for Tβ4 is a critical area for future basic research, as this would further elucidate its signaling mechanisms and could enable the development of more targeted second-generation therapies. Additionally, a more complete understanding of its in vivo metabolic pathways and its long-term safety profile, particularly with respect to the theoretical risk of tumorigenesis, will be essential for its broad clinical adoption.

9.0 Concluding Expert Analysis and Recommendations

Thymosin beta-4 (timbetasin) stands as a compelling investigational biologic with a unique, dual mechanism of action that positions it as a master regulator of tissue repair. Its development journey is a case study in both the promise of pleiotropic molecules and the significant challenges of translating that promise into regulatory approval.

9.1 Synthesis of Evidence: Strengths and Weaknesses of the Tβ4 Profile

A holistic assessment of the Tβ4 program reveals a distinct profile of strengths and weaknesses that will dictate its future trajectory.

• Strengths:
• Powerful, Pleiotropic Mechanism: Tβ4's ability to modulate multiple phases of the healing cascade—inflammation, cell migration, angiogenesis, and remodeling—gives it a therapeutic breadth that single-target molecules lack.
• Exceptional Safety Profile: The most consistent finding across all human trials is its excellent safety and tolerability, a critical asset that provides a wide therapeutic window and de-risks development.
• Strong Preclinical Validation: The robust and consistent effects observed in a wide array of animal models have successfully translated into signals of human efficacy, validating its mechanism of action.
• Clear Path to First Approval: The program in Neurotrophic Keratopathy, benefiting from orphan drug status and an objective endpoint, represents the most probable and direct path to an initial market approval.
• Favorable Commercial Outlook: The reclassification to a biologic, granting 12 years of market exclusivity upon approval, fundamentally strengthens the commercial case for the asset.
• Weaknesses:
• Challenging Pharmacokinetics: The short systemic half-life is a significant hurdle for treating acute, systemic conditions, necessitating advanced delivery solutions or intensive dosing regimens.
• Mixed Efficacy in Broad Indications: The failure to consistently meet primary endpoints in large, heterogeneous populations like Dry Eye Syndrome highlights the difficulty of demonstrating efficacy in complex, multifactorial diseases.
• Stalled Dermal Program: Development in dermal wound healing, despite a strong preclinical rationale, appears to have stalled after Phase 2 trials did not produce statistically significant results.

9.2 Assessment of Therapeutic Promise by Indication

Based on the available evidence, the therapeutic promise of Tβ4 varies significantly by indication:

• Highest Promise (Near-Term): Neurotrophic Keratopathy. This indication represents the "path of least resistance" to market. The combination of orphan drug status, a clear biological rationale for repair, an objective endpoint (wound closure), and a strong efficacy signal in the initial Phase 3 trial makes NK the most likely first approval for Tβ4.
• Moderate Promise (Longer-Term): Dry Eye Syndrome. Success in this large, commercially attractive market is still possible but will require a more nuanced strategy. Approval will likely depend on the successful execution of a highly targeted ARISE-4 trial that leverages learnings from the previous studies to enrich for responsive patient populations and endpoints, coupled with a "totality of evidence" argument presented to the FDA, heavily supported by the drug's stellar safety record.
• Exploratory Promise: Cardiovascular and Neurological Diseases. The potential impact in these areas is immense, but the clinical path is the least defined. The promising pilot data in STEMI suggests Tβ4 may be best positioned as an adjunctive therapy to enhance the efficacy of cell-based treatments rather than as a standalone monotherapy. Significant investment in formulation and delivery technology will be required to overcome the pharmacokinetic challenges for these acute indications.

9.3 Recommendations for Future Research and Clinical Development Strategy

To maximize the potential of the Thymosin beta-4 platform, a focused and strategic approach is recommended:

1. Prioritize Neurotrophic Keratopathy Approval: The primary strategic focus should be on the successful execution of the confirmatory Phase 3 trials for NK. Securing a first regulatory approval will be a transformative event, validating the therapeutic platform, providing a potential revenue stream, and significantly de-risking the asset for partners and investors.
2. Optimize the Dry Eye Syndrome Strategy: The design of the planned ARISE-4 trial is critical. It should be informed by a deep analysis of the pooled data from the first three trials to identify the patient subgroups, disease severity, and specific sign/symptom endpoints that demonstrated the most robust response to RGN-259.
3. Invest in Advanced Delivery Technology: For Tβ4 to realize its potential in systemic indications like cardiac and CNS repair, overcoming its short half-life is paramount. Future development in these areas should run parallel to research into advanced delivery systems, such as targeted nanoparticles, sustained-release hydrogels, or other formulation technologies that can ensure adequate drug exposure at the site of injury.
4. Clarify the Extracellular Mechanism: Continued basic research to definitively identify the cell surface receptor(s) for Tβ4 remains a high priority. A clearer understanding of its extracellular signaling mechanism would not only strengthen the biological narrative but could also pave the way for the rational design of more potent or targeted second-generation agonists.

Works cited

1. Professional Monograph Thymosin Beta 4 (Tb4) - Northampton Integrative Medicine, accessed September 5, 2025, https://northamptonintegrativemedicine.com/wp-content/uploads/2019/05/Thymosin-beta-4-Monograph-1.pdf
2. Thymosin beta 4 | A4M, accessed September 5, 2025, https://a4m.com/assets/pdf/covid-19-resources/Thymosin%20beta%204%20prof%20monograph.pdf
3. Progress on the Function and Application of Thymosin β4 - Frontiers, accessed September 5, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.767785/full
4. Thymosin Beta 4 and Thymosin Beta 10 Expression in Hepatocellular Carcinoma - PMC, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3980204/
5. pmc.ncbi.nlm.nih.gov, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3980204/#:~:text=Thymosin%20beta%204%20(T%CE%B24)%20is,thymosin%20family%20in%20mammalian%20tissues.&text=This%2043%20amino%20acid%20peptide,main%20actin%20monomer%20sequestering%20molecule.
6. Thymosin beta-4 - Wikipedia, accessed September 5, 2025, https://en.wikipedia.org/wiki/Thymosin_beta-4
7. Thymosin β4: A multi-functional regenerative peptide. Basic properties and clinical applications - ResearchGate, accessed September 5, 2025, https://www.researchgate.net/publication/51790225_Thymosin_b4_A_multi-functional_regenerative_peptide_Basic_properties_and_clinical_applications
8. Histological Evaluation of Effect of Thymosin Beta 4 on Wound Healing of Skin, accessed September 5, 2025, https://www.ejdent.org/index.php/ejdent/article/view/330
9. Thymosin β 4, Human - GenScript, accessed September 5, 2025, https://www.genscript.com/protein/Z02908-Thymosin_4_Human.html
10. Animal studies with thymosin 4, a multifunctional tissue repair and regeneration peptide - Paulina Medical Clinic, accessed September 5, 2025, https://www.paulinamedicalclinic.com/wp-content/uploads/2019/11/Animal-studies-with-thymosin-beta4-a-multifunctional-tissue-repair-and-regeneration-peptide-1.pdf
11. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/22074294/
12. Advances in the basic and clinical applications of thymosin β4 - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/26096726/
13. Progress on the Function and Application of Thymosin β4 - PMC - PubMed Central, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/
14. Thymosin β4: structure, function, and biological properties supporting current and future clinical applications, accessed September 5, 2025, https://peptidesociety.org/wp-content/uploads/2017/10/Crockford_et_al-2010-Annals_of_the_New_York_Academy_of_Sciences.pdf
15. Thymosin beta4 accelerates wound healing - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/10469335/
16. Thymosin beta-4: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 5, 2025, https://go.drugbank.com/drugs/DB12003
17. thymosin beta(4) MeSH Supplementary Concept Data 2024, accessed September 5, 2025, https://meshb-prev.nlm.nih.gov/record/ui?ui=C033402
18. THYMOSIN .BETA.-4 - Inxight Drugs, accessed September 5, 2025, https://drugs.ncats.io/drug/549LM7U24W
19. Thymosin beta 4 (Thymosin beta-4) API ... - Pharmaoffer.com, accessed September 5, 2025, https://pharmaoffer.com/api-excipient-supplier/hormonal-agents/thymosin%20beta%204
20. zellbio.eu, accessed September 5, 2025, https://zellbio.eu/product/thymosin-beta-4/#:~:text=Thymosin%20b4%20is%20a%2043,56O78S1.
21. Thymosin beta 4 Hormone - Prospec Bio, accessed September 5, 2025, https://www.prospecbio.com/thymosin_beta-4
22. Thymosin Beta 4 | C212H350N56O78S | CID 45382195 - PubChem, accessed September 5, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/45382195
23. Thymosin beta4: Actin Regulation and More | Request PDF - ResearchGate, accessed September 5, 2025, https://www.researchgate.net/publication/5897290_Thymosin_beta4_Actin_Regulation_and_More
24. Thymosin Beta 4 - Blog - GlpBio, accessed September 5, 2025, https://www.glpbio.com/blog/post/thymosin-beta-4.html
25. www.chemicalbook.com, accessed September 5, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4409683.htm#:~:text=T%CE%B24%20is%20a%20water%E2%80%90soluble,which%20are%20glutamate%20and%20glycine.
26. Structural basis of thymosin-β4/profilin exchange leading to actin ..., accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4217450/
27. (PDF) Nuclear localisation of the G-actin sequestering peptide thymosin 4 - ResearchGate, accessed September 5, 2025, https://www.researchgate.net/publication/8248553_Nuclear_localisation_of_the_G-actin_sequestering_peptide_thymosin_4
28. Structural basis of actin sequestration by thymosin-β4: implications for WH2 proteins - PMC - PubMed Central, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC517612/
29. THYMOSIN Beta-4 (TB-500) - Particle Peptides, accessed September 5, 2025, https://particlepeptides.com/en/content/28-thymosine-beta-4-tb500
30. Role of Thymosin β4 in Tumor Metastasis and Angiogenesis | JNCI ..., accessed September 5, 2025, https://academic.oup.com/jnci/article/95/22/1674/2606660
31. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent, accessed September 5, 2025, https://www.researchgate.net/publication/26730063_Thymosin_beta_4_A_novel_corneal_wound_healing_and_anti-inflammatory_agent
32. Transplantation of Endothelial Progenitor Cells in Obese Diabetic Rats Following Myocardial Infarction: Role of Thymosin Beta-4 - MDPI, accessed September 5, 2025, https://www.mdpi.com/2073-4409/9/4/949
33. Thymosin beta4 induces angiogenesis through Notch signaling in endothelial cells | Request PDF - ResearchGate, accessed September 5, 2025, https://www.researchgate.net/publication/237095096_Thymosin_beta4_induces_angiogenesis_through_Notch_signaling_in_endothelial_cells
34. Thymosin β4 promotes angiogenesis and increases muscle progenitor cell density in ischemic skeletal muscle in a mouse model of hind limb ischemia - Scientific Research Publishing, accessed September 5, 2025, https://www.scirp.org/journal/paperinformation?paperid=22539
35. Tβ4 - ReGenTree, accessed September 5, 2025, https://www.regentreellc.com/?c=tbeta4
36. New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease - Oct 5, 2021 - RegeneRx, accessed September 5, 2025, https://www.regenerx.com/2021-10-05-New-Research-Demonstrates-Thymosin-Beta-4s-Potential-Positive-Effects-on-Alzheimers-Disease
37. Essential Role for Thymosin β4 in Regulating Vascular Smooth Muscle Cell Development and Vessel Wall Stability - AHA Journals, accessed September 5, 2025, https://www.ahajournals.org/doi/10.1161/circresaha.111.259846
38. Different Thymosin Beta 4 Immunoreactivity in Foetal and Adult Gastrointestinal Tract, accessed September 5, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009111
39. Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles - Dove Medical Press, accessed September 5, 2025, https://www.dovepress.com/targeted-delivery-of-thymosin-beta-4-to-the-injured-myocardium-using-c-peer-reviewed-fulltext-article-IJN
40. Thymosin-β4: A key modifier of renal disease - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/29727205/
41. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers | Request PDF - ResearchGate, accessed September 5, 2025, https://www.researchgate.net/publication/44662023_A_randomized_placebo-controlled_single_and_multiple_dose_study_of_intravenous_thymosin_b4_in_healthy_volunteers
42. pmc.ncbi.nlm.nih.gov, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3392183/#:~:text=The%20mean%20half%2Dlife%20of,hours%20at%201260%20mg%2Fsubject.&text=Whether%20the%20higher%20dose%20of,study%20is%20optimal%20remains%20unknown.
43. EP2311485A1 - Thymosin beta 4 promotes wound repair - Google Patents, accessed September 5, 2025, https://patents.google.com/patent/EP2311485A1/en
44. Thymosin β4 Promotes Dermal Healing - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/27450738/
45. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/15037013/
46. Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries | IOVS, accessed September 5, 2025, https://iovs.arvojournals.org/article.aspx?articleid=2423767
47. Recombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease - MDPI, accessed September 5, 2025, https://www.mdpi.com/1422-0067/23/10/5458
48. Thymosin Beta 4 Is Dispensable for Murine Cardiac Development and Function, accessed September 5, 2025, https://www.ahajournals.org/doi/10.1161/circresaha.111.258616
49. Thymosin Beta‐4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction, accessed September 5, 2025, https://www.ahajournals.org/doi/10.1161/jaha.117.005586
50. Neuroprotective and neurorestorative effects of thymosin beta4 treatment initiated 6 hours post injury following traumatic brain injury in rats - PMC - PubMed Central, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3392183/
51. Neuroprotective and neurorestorative effects of Thymosin beta 4 treatment following experimental traumatic brain injury - PMC - PubMed Central, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3547647/
52. Neuroprotective and Neurorestorative Effects of Thymosin Beta4 Treatment after Traumatic Brain Injury (S21.004) - Neurology.org, accessed September 5, 2025, https://www.neurology.org/doi/10.1212/WNL.82.10_supplement.S21.004
53. Neuroprotective Effects of Thymosin β4 in Experimental Models of Excitotoxicity, accessed September 5, 2025, https://www.researchgate.net/publication/5897292_Neuroprotective_Effects_of_Thymosin_b4_in_Experimental_Models_of_Excitotoxicity
54. Thymosin Beta 4 Protects Hippocampal Neuronal Cells against PrP (106–126) via Neurotrophic Factor Signaling - MDPI, accessed September 5, 2025, https://www.mdpi.com/1420-3049/28/9/3920
55. Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/12860178/
56. Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing - PubMed, accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/23820300/
57. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model - PMC - PubMed Central, accessed September 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4445951/
58. Thymosin β4 significantly improves signs and symptoms of severe ..., accessed September 5, 2025, https://pubmed.ncbi.nlm.nih.gov/25826322/
59. RGN-259 - RegeneRx, accessed September 5, 2025, https://www.regenerx.com/RGN-259
60. RegeneRx Management Presentation, accessed September 5, 2025, http://filecache.investorroom.com/mr5ir_regenerx_ir/184/RGRX%202021%20Annual%20Meeting%20Presentation%20v2.pdf
61. Thymosin beta-4 Completed Phase 3 Trials for Dry Eye Syndrome (DES) / Dry Eyes Treatment - DrugBank, accessed September 5, 2025, https://go.drugbank.com/drugs/DB12003/clinical_trials?conditions=DBCOND0074986%2CDBCOND0054254&phase=3&purpose=treatment&status=completed
62. Dry Eye Disease(DED) - ReGenTree, accessed September 5, 2025, https://www.regentreellc.com/?c=pipeline/des
63. RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease - Oct 24, 2022, accessed September 5, 2025, https://www.regenerx.com/2022-10-24-RegeneRx-Licensee-Submits-Special-Protocol-Assessment-to-FDA-for-4th-Phase-3-Clinical-Trial-for-Dry-Eye-Disease
64. RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome - FirstWord Pharma, accessed September 5, 2025, https://firstwordpharma.com/story/5299827
65. Thymosin Beta 4 Eye Drops Significantly Improve Signs and Symptoms of Severe Dry Eye in a Physician-Sponsored Phase 2 Clinical Trial | IOVS, accessed September 5, 2025, https://iovs.arvojournals.org/article.aspx?articleid=2151041
66. Search Orphan Drug Designations and Approvals - FDA, accessed September 5, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=416613
67. Thymosin beta-4 Recruiting Phase 3 Trials for Neurotrophic Keratopathy Treatment, accessed September 5, 2025, https://go.drugbank.com/drugs/DB12003/clinical_trials?conditions=DBCOND0077055&phase=3&purpose=treatment&status=recruiting
68. Thymosin beta-4 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 5, 2025, https://synapse.patsnap.com/drug/dff6fd0a148f470bac5f151bb7fa698e
69. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial - MDPI, accessed September 5, 2025, https://www.mdpi.com/1422-0067/24/1/554
70. Advances in the basic and clinical applications of thymosin β4 ..., accessed September 5, 2025, https://www.researchgate.net/publication/278968856_Advances_in_the_basic_and_clinical_applications_of_thymosin_b4
71. Varicose Ulcers Completed Phase 2 Trials for Thymosin beta-4 (DB12003) - DrugBank, accessed September 5, 2025, https://go.drugbank.com/indications/DBCOND0032264/clinical_trials/DB12003?phase=2&status=completed
72. Epidermolysis Bullosa (EB) Terminated Phase 2 Trials for Thymosin beta-4 (DB12003), accessed September 5, 2025, https://go.drugbank.com/indications/DBCOND0126399/clinical_trials/DB12003?phase=2&status=terminated
73. Thymosin Beta 4 Effective in Treatment of Heart Attack Patients - Jun ..., accessed September 5, 2025, https://www.regenerx.com/2016-06-14-Thymosin-Beta-4-Effective-in-Treatment-of-Heart-Attack-Patients
74. Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure | Fierce Pharma, accessed September 5, 2025, https://www.fiercepharma.com/pharma-asia/clinical-trial-demonstrates-elevated-thymosin-beta-4-plasma-levels-are-associated-0
75. RegeneRx Advisory on Reclassification of Thymosin Beta 4 from Drug to Biologic, accessed September 5, 2025, https://www.prnewswire.com/news-releases/regenerx-advisory-on-reclassification-of-thymosin-beta-4-from-drug-to-biologic-301066219.html
76. RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome - Apr 9, 2018, accessed September 5, 2025, https://www.regenerx.com/2018-04-09-RegeneRx-Announces-Outcome-of-FDA-Discussions-for-Development-of-RGN-259-for-Dry-Eye-Syndrome
77. Animal studies with thymosin beta4, a multifunctional tissue repair and regeneration peptide | Request PDF - ResearchGate, accessed September 5, 2025, https://www.researchgate.net/publication/238538186_Animal_studies_with_thymosin_beta4_a_multifunctional_tissue_repair_and_regeneration_peptide
78. Thymosin beta 4 - Safety Data Sheet - ChemicalBook, accessed September 5, 2025, https://www.chemicalbook.com/msds/Thymosin-beta-4.pdf
79. Safety Data Sheet - Cayman Chemical, accessed September 5, 2025, https://cdn.caymanchem.com/cdn/msds/28605m.pdf
80. Safety Data Sheet - MedchemExpress.com, accessed September 5, 2025, https://file.medchemexpress.com/batch_PDF/HY-P72776/Thymosin-beta-4-Protein-Human-SDS-MedChemExpress.pdf
81. Is Thymosin Beta-4 (TB4) effective? - Dr.Oracle AI, accessed September 5, 2025, https://www.droracle.ai/articles/20240/is-thymosin-beta-4-tb4-effective
82. TB4 and TB-500 Peptide Therapy | What to Know in 2025 - Innerbody, accessed September 5, 2025, https://www.innerbody.com/thymosin-beta-4-and-tb-500
83. The Unregulated World of Peptides: What You Need to Know Before You Inject - Holt Law, accessed September 5, 2025, https://djholtlaw.com/the-unregulated-world-of-peptides-what-you-need-to-know-before-you-inject/
84. Is TB-500 (thymosin beta-4) peptide safe and effective for wound healing and tissue repair?, accessed September 5, 2025, https://www.droracle.ai/articles/234878/tb-500-peptide
85. European Medicines Agency (EMA), accessed September 5, 2025, https://www.ema.europa.eu/en/medicines
86. ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ, accessed September 5, 2025, https://immunitybio.com/immunitybio-announces-european-medicines-agency-acceptance-of-marketing-authorization-application-for-anktiva-for-the-treatment-of-patients-with-bcg-unresponsive-non-muscle-invasive-bladder-canc/
87. ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ, accessed September 5, 2025, https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-european-medicines-agency-acceptance
88. Medicines for human use under evaluation | European Medicines Agency (EMA), accessed September 5, 2025, https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation
89. EMA drug regulation and approval news | The Pharmaletter, accessed September 5, 2025, https://www.thepharmaletter.com/ema
90. Reclassification of Thymosin Beta 4 from New Drug Entity to Biologic - RegeneRx, accessed September 5, 2025, https://www.regenerx.com/2020-05-27-Reclassification-of-Thymosin-Beta-4-from-New-Drug-Entity-to-Biologic